From: Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
SGLT2i or GLP-1 RA | Standardized Difference (%)a | ||
---|---|---|---|
Yes n = 2348 | No n = 12,228 | ||
Patient factors at enrollment | |||
Age (years) | 56.1 ± 11.5 | 57.7 ± 12.1 | 13.8 |
Female | 42.4% | 46.8% | 8.8 |
Education level | 26.2 | ||
Primary or none | 10.1% | 20.0% | |
Secondary | 51.6% | 49.1% | |
University | 37.3% | 30.9% | |
Current smoker | 18.0% | 12.5% | 21.5 |
Body mass index (kg/m2) | 31.8 ± 6.5 | 28.9 ± 5.8 | 47.0 |
Duration of diabetes | 5.6 ± 5.0 | 5.8 ± 5.3 | 3.9 |
HbA1c (%) | 8.3 ± 1.6 | 8.3 ± 1.7 | 2.6 |
Creatinine (mg/dL) | 0.9 ± 1.0 | 1.0 ± 1.0 | 5.1 |
Specialty of Main Investigator | 28.3 | ||
Primary care | 20.2% | 31.4% | |
Endocrinology | 74.0% | 65.5% | |
Cardiology | 4.7% | 2.4% | |
Other | 1.1% | 0.7% | |
Region | 60.3 | ||
Africa | 0.6% | 6.5% | |
Americas | 18.1% | 12.8% | |
Europe | 34.1% | 21.8% | |
Middle East | 11.7% | 15.5% | |
Southeast Asia | 10.3% | 25.4% | |
Western Pacific | 25.2% | 17.9% | |
Comorbidities at last follow-up | |||
Coronary artery disease | 14.8% | 10.1% | 14.4 |
Cerebrovascular disease | 2.9% | 2.9% | 0.2 |
Heart failure | 7.5% | 4.3% | 13.2 |
Peripheral artery disease | 3.4% | 3.3% | 0.6 |
Chronic kidney disease | 6.1% | 5.1% | 4.6 |